HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

buflomedil (Lofton)

RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure

Also Known As:

Lofton; 1A brand of buflomedil hydrochloride; 2,4,6-trimethoxyphenyl-3-pyrrolidine propyl ketone; AbZ brand of buflomedil hydrochloride; Abbott brand of buflomedil hydrochloride; Alpharma brand of buflomedil hydrochloride; Bufedil; Buflo 1A Pharma; Buflo AbZ; Buflo-POS; Buflo-Puren; Buflohexal; Buflomedil Heumann; Buflomedil Lindo; Buflomedil Stada; Buflomedil-ratiopharm; Fonzylane; Heumann brand of buflomedil hydrochloride; Hexal brand of buflomedil hydrochloride; Hosbon brand of buflomedil hydrochloride; LL 1656; Lafon brand of buflomedil hydrochloride; Lindopharm brand of buflomedil hydrochloride; Loftyl; Sinoxis; Stadapharm brand of buflomedil hydrochloride; Ursapharm brand of buflomedil hydrochloride; blufomedil; buflomedil hydrochloride; buflomedil pyridoxal phosphate; buflomedil von ct; bufomedil; ct-Arzneimittel brand of buflomedil hydrochloride; ratiopharm brand of buflomedil hydrochloride; 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone

Networked: 119 relevant articles (17 outcomes, 28 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 9
    - buflomedil: 119

Experts

1.	Vander Stichele, Robert H: 2 articles (01/2009 - 09/2008)
2.	Van Bortel, Luc M: 2 articles (01/2009 - 09/2008)
3.	de Backer, T L M: 2 articles (01/2008 - 01/2007)
4.	Bogaert, M: 2 articles (01/2008 - 01/2007)
5.	Vander Stichele, R: 2 articles (01/2008 - 01/2007)
6.	Wu, Simiao: 1 article (01/2015)
7.	He, Sha: 1 article (01/2015)
8.	Liu, Ming: 1 article (01/2015)
9.	Lin, Sen: 1 article (01/2015)
10.	Zeng, Quantao: 1 article (01/2015)

Related Diseases

1.	Intermittent Claudication 12/01/2001 - "These findings suggest the therapeutic efficacy of buflomedil in diabetic subjects with intermittent claudication. " 01/01/2001 - "There is a lack evidence for the efficacy of buflomedil in intermittent claudication." 01/01/2001 - "There is little evidence available to evaluate the efficacy of buflomedil for intermittent claudication. " 01/01/2001 - "To evaluate the available evidence on the efficacy of buflomedil for intermittent claudication. " 02/12/2008 - "We performed an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate whether long-term administration of oral buflomedil could reduce the rate of cardiovascular events in patients with intermittent claudication. "
2.	Peripheral Arterial Disease 01/01/1982 - "Protective effects of buflomedil against exercise-induced reductions in regional erythrocyte deformability of patients with peripheral arterial disease." 02/12/2008 - "Buflomedil in peripheral arterial disease: trials and tribulations." 01/01/2015 - "Buflomedil is a vasoactive agent that has been used for peripheral arterial diseases. " 10/01/2008 - "Buflomedil reduced cardiovascular events in peripheral arterial disease." 01/01/1989 - "Buflomedil is a vasoactive agent widely used in the treatment of peripheral arterial disease. "
3.	Stroke (Strokes) 01/01/2015 - "We included randomised controlled trials (RCTs) that investigated the efficacy of buflomedil in people with acute ischaemic stroke. " 01/01/2015 - " one trial reported long-term death and disability, where stroke survivors in the buflomedil group had a lower risk of suffering 'death or disability' than those in the control group (200 participants, RR 0.71, 95% confidence interval (CI) 0.53 to 0.94). " 01/01/2015 - "Given these uncertainties, the data support the rationale for an adequately powered RCT of buflomedil in people with acute ischaemic stroke." 01/01/2015 - "There is insufficient evidence on the efficacy or safety of buflomedil to support its use for the treatment of acute ischaemic stroke. " 01/01/2015 - "To assess the efficacy and safety of buflomedil for the treatment of acute ischaemic stroke. "
4.	Alzheimer Disease (Alzheimer's Disease) 05/01/1990 - "Tolerance of long-term buflomedil was assessed by compiling safety data (adverse effects, vital signs and clinical laboratory results) from three multicentre clinical trials in patients with intermittent claudication or Alzheimer's disease-type senile dementia. " 01/01/1985 - "Seventy-six patients took part in a randomized, comparative study of the efficacy of buflomedil hydrochloride and dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency. " 01/01/1985 - "In conclusion, buflomedil is as effective or more effective than dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency and could prove a valuable addition to long-term therapy if further studies support the trend shown in this study." 01/01/1985 - "The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids." 05/01/1987 - "In patients with symptoms presumed to be due to cerebrovascular insufficiencies and elderly patients with senile dementia, buflomedil 450 to 600 mg/day alleviated symptoms associated with impairment of cognitive and psychometric function and was significantly superior to placebo and slightly more effective than drugs such as cinnarizine, flunarizine and co-dergocrine mesylate. "
5.	Peripheral Vascular Diseases (Peripheral Vascular Disease) 01/01/2013 - "Buflomedil is a vasoactive agent used to treat peripheral vascular disease. " 01/01/2008 - "Buflomedil is a vasoactive agent used to treat peripheral vascular disease. " 01/01/2007 - "Buflomedil is a vasoactive agent used to treat peripheral vascular disease. " 05/01/1996 - "Buflomedil (CAS 55837-25-7, Fonzylane) is a peripherally vasoactive drug which improves nutritional blood flow in ischaemic tissue of patients with peripheral vascular disease by the way of an increase of perfusion in the microcirculation. " 05/01/1992 - "The aim was to evaluate whether buflomedil (a drug used to treat peripheral vascular disease and which has a number of pharmacological actions potentially beneficial to dysfunctional myocardium) would preserve myocardial function after transient coronary artery occlusion followed by reperfusion. "

Related Drugs and Biologics

1.	Nafronyl (Naftidrofuryl)
2.	Pentoxifylline (Trental)
3.	Oxygen
4.	Ergot Alkaloids
5.	Nifedipine (Adalat)
6.	Nicergoline
7.	Cinnarizine (Cinna)
8.	Vasodilator Agents (Vasodilators)
9.	Epoprostenol (Prostacyclin)
10.	Mesylates (Mesylate)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Intravenous Infusions
3.	Oral Administration
4.	Tourniquets
5.	Aftercare (After-Treatment)